

Please type a plus sign (+) in this box +

PTO/SB (12-97)
Approved for use through 9/30/00 OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number 10/770,639	
				Filing Date February 2, 2004	
				First Named Inventor Sanchez-Madrid	
				Group Art Unit 1644	
				Examiner Name Zachary S. Skelding	
				Attorney Docket Number 27331-501 CIP2A	

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

U.S. PUBLISHED APPLICATION DOCUMENTS							
Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes	No	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS							
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.					
	C1	Ziegler, S.F. et al. (1993) Molecular characterization of the early activation antigen CD69: a type II membrane glycoprotein related to a family of natural killer cell activation antigens. Eur. J. Immunol. 23, 1643–1648					
	C2	López-Cabrera, M. et al. (1993) Molecular cloning, expression, and chromosomal localization of the human earliest lymphocyte activation antigen AIM/CD69, a new member of the C-type animal lectin superfamily of signal-transmitting receptors. J. Exp. Med. 178, 537–547					
	C3	Testi, R. et al. (1994) The CD69 receptor: a multipurpose cell-surface trigger for hematopoietic cells. Immunol. Today 15, 479–483					
	C4	Long, E.O. (1999) Regulation of immune responses through inhibitory receptors. Annu. Rev. Immunol. 17, 875–904					
	C5	Pisegna, S. et al. (2002) Src-dependent Syk activation controls CD69-mediated signaling and function on human NK cells. J. Immunol. 169, 68–74					
	C6	Zingoni, A. et al. (2000) CD69-triggered ERK activation and functions are negatively regulated by CD94/NKG2-A inhibitory receptor. Eur. J. Immunol. 30, 644–651					
	C7	Risso, A. et al. (1991) CD69 in resting and activated T lymphocytes. Its association with a GTP binding protein and biochemical requirements for its expression. J. Immunol. 146, 4105–4114					
	C8	Bikah, G. et al. (2000) Regulating T helper cell immunity through antigen responsiveness and calcium entry. Nat. Immunol. 1, 402–412					
	C9	Sancho, D. et al. (2000) Functional analysis of ligand-binding and signal transduction domains of CD69 and CD23 C-type lectin leukocyte receptors. J. Immunol. 165, 3868–3875					

C10	Testi, R. et al. (1989) T cell activation via Leu-23 (CD69). <i>J. Immunol.</i> 143, 1123-1128
C11	Cebrián, M. et al. (1988) Triggering of T cell proliferation through AIM, an activation inducer molecule expressed on activated human lymphocytes. <i>J. Exp. Med.</i> 168, 1621-1637
C12	Santis, A.G. et al. (1992) Tumor necrosis factor- α production induced in T lymphocytes through the AIM/CD69 activation pathway. <i>Eur. J. Immunol.</i> 22, 1253-1259
C13	De-Maria, R. et al. (1994) Triggering of human monocyte activation through CD69, a member of the natural killer cell gene complex family of signal transducing receptors. <i>J. Exp. Med.</i> 180, 1999-2004
C14	Testi, R. et al. (1990) CD69 is expressed on platelets and mediates platelet activation and aggregation. <i>J. Exp. Med.</i> 172, 701-707
C15	Ramírez, R. et al. (1996) CD69-induced monocyte apoptosis involves multiple nonredundant signaling pathways. <i>Cell. Immunol.</i> 172, 192-199
C16	Walsh, G.M. et al. (1996) Ligation of CD69 induces apoptosis and cell death in human eosinophils cultured with granulocyte-macrophage colony-stimulating factor. <i>Blood</i> 87, 2815-2821
C17	Cosulich, M.E. et al. (1987) Functional characterization of an antigen involved in an early step of T-cell activation. <i>Proc. Natl. Acad. Sci. U. S. A.</i> 84, 4205-4209
C18	Feng, C. et al. (2002) A potential role for CD69 in thymocyte emigration. <i>Int. Immunol.</i> 14, 535-544
C19	Nakayama, T. et al. (2002) The generation of mature, single-positive thymocytes in vivo is dysregulated by CD69 blockade or overexpression. <i>J. Immunol.</i> 168, 87-94
C20	Lanzurica, P. et al. (2000) Phenotypic and functional characteristics of hematopoietic cell lineages in CD69-deficient mice. <i>Blood</i> 95, 2312-2320
C21	Laffón, A. et al. (1991) Upregulated expression and function of VLA-4 fibronectin receptors on human activated T cells in rheumatoid arthritis. <i>J. Clin. Invest.</i> 88, 546-552
C22	Remmers, E.F. et al. (1996) A genome scan localizes five non-MHC loci controlling collagen-induced arthritis in rats. <i>Nat. Genet.</i> 14, 82-85
C23	Mc Indoe, R.A. et al. (1999) Localization of non-MHC collagen-induced arthritis susceptibility loci in DBA/1j mice. <i>Proc. Natl. Acad. Sci. U. S. A.</i> 96, 2210-2214
C24	Brandes, M.E. et al. (1991) Transforming growth factor b1 suppresses acute and chronic arthritis in experimental animals. <i>J. Clin. Invest.</i> 87, 1108-1113
C25	Grewal, J.S. et al. (1999) Serotonin 5-HT _{2A} receptor induces TGF- β 1 expression in mesangial cells via ERK: proliferative and fibrotic signals. <i>Am. J. Physiol. Renal Physiol.</i> 276, F922-F930
C26	Gorelik, L. and Flavell, R.A. (2001) Immune-mediated eradication of tumors through the blockade of transforming growth factor- β signaling in T cells. <i>Nat. Med.</i> 7, 1118-1122
C27	Gorelik, L. et al. (2002) Mechanism of transforming growth factor β -induced inhibition of T helper type 1 differentiation. <i>J. Exp. Med.</i> 195, 1499-1505
C28	Cazac, B.B. and Roes, J. (2000) TGF- β receptor controls B cell responsiveness and induction of IgA in vivo. <i>Immunity</i> 13, 443-451
C29	Fava, R.A. et al. (1991) Transforming growth factor β induced neutrophil recruitment to synovial tissues: implications for TGF- β driven synovial inflammation and hyperplasia. <i>J. Exp. Med.</i> 173, 1121-1132
C30	Sancho, D. et al. (1999) Activation of peripheral blood T cells by interaction and migration through endothelium: role of lymphocyte function antigen-1/intercellular adhesion molecule-1 and interleukin-15. <i>Blood</i> 93, 886-896
C31	Fava, R. et al. (1989) Active and latent forms of transforming growth factor β activity in synovial effusions. <i>J. Exp. Med.</i> 169, 291-296
C32	Yu, X. et al. (2001) Anti-CD69 autoantibodies cross-react with low density lipoprotein receptor-related protein 2 in systemic autoimmune diseases. <i>J. Immunol.</i> 166, 1360-1369
C33	Kulkarni, A.B. et al. (1993) Transforming growth factor β 1 null mutation in mice causes excessive inflammatory response and early death. <i>Proc. Natl. Acad. Sci. U. S. A.</i> 90, 770-774
C34	Shull, M.M. et al. (1992) Targeted disruption of the mouse transforming growth factor- β 1 gene results in multifocal inflammatory disease. <i>Nature</i> 359, 693-699
C35	Shevach, E.M. (2002) CD4 ⁺ CD25 ⁺ suppressor T-cells: more questions than answers. <i>Nat. Rev. Immunol.</i>

Date of Deposit: May 18, 2007

Attorney Docket No.: 27331-501 CIP2A

		2, 389–400
	C36	Chatenoud, L. et al. (1997) Induced dominant self-tolerance in overtly diabetic NOD mice. <i>J. Immunol.</i> 158, 2947–2954
	C37	Ishikawa, S. et al. (1998) A subset of CD4 ⁺ T cells expressing early activation antigen CD69 in murine lupus: possible abnormal regulatory role for cytokine imbalance. <i>J. Immunol.</i> 161, 1267–1273
	C38	Portales-Perez, D. et al. (1997) Abnormalities in CD69 expression, cytosolic pH and Ca ²⁺ during activation of lymphocytes from patients with systemic lupus erythematosus. <i>Lupus</i> 6, 48–56
	C39	Hernández-García, C. et al. (1996) The CD69 activation pathway in rheumatoid arthritis synovial fluid T cells. <i>Arthritis Rheum.</i> 39, 1277–1286
	C40	McGuirk, P. and Mills, L. (2002) Pathogen-specific regulatory T cells provoke a shift in the Th1/Th2 paradigm in immunity to infectious diseases. <i>Trends Immunol.</i> 23, 450–455
	C41	Swat, W. et al. (1993) CD69 expression during selection and maturation of CD4 ⁺ CD8 ⁺ thymocytes. <i>Eur. J. Immunol.</i> 23, 739–746
	C42	Bendelac, A. et al. (1992) Activation events during thymic selection. <i>J. Exp. Med.</i> 175, 731–742
	C43	Yamashita, I. et al. (1993) CD69 cell surface expression identifies developing thymocytes which audition for T cell antigen receptor mediated positive selection. <i>Int. Immunol.</i> 5, 1139–1150
	C44	Hare, K.J. et al. (1999) CD69 expression discriminates MHC dependent and -independent stages of thymocyte positive selection. <i>J. Immunol.</i> 162, 3978–3983

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ACTIVE 4043457v.1